{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:25:59Z","timestamp":1648992359166},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/01.jaa.0000480576.16121.88","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T08:01:18Z","timestamp":1456473678000},"page":"25-26","source":"Crossref","is-referenced-by-count":0,"title":["Who should receive extended infusion beta-lactam therapy?"],"prefix":"10.1097","volume":"29","author":[{"given":"Christopher","family":"Roman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tia","family":"Solh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra M.","family":"Damer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1","key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.diagmicrobio.2014.07.007","article-title":"Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit.","volume":"80","author":"Rahme","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current -lactam antibiotic doses sufficient for critically ill patients.","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokineticpharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents.","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams.","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial -lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"issue":"6","key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcrc.2014.07.033","article-title":"Prolonged vs intermittent infusion of piperacillintazobactam in critically ill patients:a narrative and systematic review.","volume":"29","author":"Yusuf","year":"2014","journal-title":"J Crit Care"},{"issue":"2","key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"issue":"2","key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2013.10.021","article-title":"Prolonging -lactam infusion: a review of the rationale and evidence, and guidance for implementation.","volume":"43","author":"MacVane","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/IPC.0b013e31822e9bf5","article-title":"Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center.","volume":"19","author":"Dow","year":"2011","journal-title":"Infect Dis Clin Pract"},{"issue":"9","key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.diagmicrobio.2009.03.002","article-title":"Outcomes of extended infusion piperacillintazobactam for documented Gram-negative infections.","volume":"64","author":"Patel","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.clinthera.2012.11.005","article-title":"Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"issue":"7","key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2014.01.027","article-title":"Prolonged infusion versus intermittent boluses of -lactam antibiotics for treatment of acute infections: a meta-analysis.","volume":"43","author":"Teo","year":"2014","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of the American Academy of Physician Assistants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000480576.16121.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:45:44Z","timestamp":1620931544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201603000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000480576.16121.88","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}